



TAVEXIA LIFECARE LIMITED
(FORMERLY SATTVA SUKUN LIFECARE LIMITED)
CIN: L27509MH1980PLC329224

Date: 12/10/2026

**To,
BSE Limited
Department of Corporate Services,
Ground Floor, P.J. Tower,
Dalal Street, Mumbai-400 001**

Scrip ID – TAVEXIA.
Scrip Code: 539519

Subject: Tavexia Lifecare Announces Strategic Expansion: Acquires 60% Controlling Stake in Meyonex Pharmaceuticals for ₹67.19 Crore

MUMBAI – October 12, 2026 – Tavexia Lifecare Limited (formerly Sattva Sukun Lifecare Limited) (BSE: 539519) today announced a major strategic expansion and a refreshed corporate identity aimed at capitalizing on emerging opportunities in the pharmaceutical, wellness, and lifecare sectors. As a key milestone in this transformational roadmap, the company's Board of Directors has approved the acquisition of a 60% controlling equity stake in Meyonex Pharmaceuticals Limited.

The acquisition, valued at ₹67.19 Crore, will be executed through a cash subscription of 2,09,97,180 fresh equity shares at an issue price of ₹32 per share. This strategic move provides Tavexia Lifecare with an immediate operational foothold via Meyonex's established manufacturing and commercial operations situated in MIDC Tarapur, Maharashtra.
Broadening into High-Margin Verticals

Demonstrating foresight in a rapidly evolving market, Tavexia has altered its Main Object Clause under its Memorandum of Association to open significant new avenues.

The company is aggressively expanding into several high-growth segments, including:

- Active Pharmaceutical Ingredients (APIs) & Bulk Drugs: Expanding into the core building blocks of global medicine.
- Finished Dosage Forms & Formulations: Moving up the value chain with tablets, capsules, injectables, and advanced delivery formats.
- CDMO & CRAMS Services: Venturing into Contract Research and Manufacturing Services (CRAMS) and Contract Development and Manufacturing Organizations (CDMO) to cater to rising domestic and international demand.
- Nutraceuticals & Biotechnology: Tapping into consumer-driven preventive healthcare and life sciences.

Financing and Strategic Outlook

The acquisition of Meyonex is expected to deliver significant synergies, providing an immediate growth runway that enables Tavexia to scale its revenue baseline and leverage operational efficiencies. To finance this well-capitalized roadmap, the management has initiated plans for strategic fund-raising through permissible equity or convertible instruments, ensuring capital discipline while backing accretive growth.



TAVEXIA LIFECARE LIMITED
(FORMERLY SATTVA SUKUN LIFECARE LIMITED)
CIN: L27509MH1980PLC329224

The company is positioning itself to benefit from sustained sector tailwinds, including support for domestic manufacturing, global supply-chain diversification ("China+1" strategies), and escalating demand for specialized generic formulations. By pivoting decisively into contract manufacturing and scalable pharma assets, Tavexia Lifecare's management aims to build a resilient platform designed to unlock substantial long-term value.

About Tavexia Lifecare Limited:

Tavexia Lifecare Limited (formerly Sattva Sukun Lifecare Limited) is a BSE-listed company (Scrip Code: 539519) headquartered in Kandivali (West), Mumbai. The company is focused on high-margin growth within the pharmaceutical and lifecare landscape.

Media Contact

Prachi Sangoi

Email: prachi@proseintegrated.com

Contact: 9004688093

Website: www.tavexia.com

Please take the same on your record and acknowledge the receipt of the same

Thanking You,
Yours Faithfully

For Tavexia Lifecare Limited
(Formerly known as: Sattva Sukun Lifecare Limited)

Poonam Rani

Digitally signed by Poonam Rani
Date: 2026.10.12 18:39:19 +05'30'

Poonam Rani
Company Secretary